News

Seeking Recession-Proof Stocks? RBC Suggests 2 Healthcare Stocks to Buy
President Trump’s newly announced tariff policy has done more than just push the stock markets deeper into correction territory — the sudden ...
Deutsche Bank Sticks to Their Hold Rating for Sanofi (SNYNF)
In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on Sanofi (SNYNF – Research Report), with a price ...
Medical Dialogues3d
Sanofi Consumer Healthcare India: CFO Maithilee Mistry, Head of Commercial Operations Rupendra Sachdev to step down
Mumbai: Sanofi Consumer Healthcare India Limited has announced the upcoming departure of two of its senior leaders.Maithilee ...
Managed Healthcare Executive6d
Costs of Hemophilia With Inhibitors Are High, Warranting Better Management | AMCP Annual 2025
The FDA has recently approved two new prophylactic treatments for people with hemophilia who develop antibodies to clotting ...
Clinical Advisor6d
Qfitlia, a Novel Treatment for Hemophilia A or B, Gets FDA Approval
Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.
Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure
A bankruptcy court in Texas rejected J&J’s proposed bankruptcy plan to settle claims related to its talc lawsuits for the ...
Texas Court Rejects J&J’s Bankruptcy Attempt to End Talc Suits
A bankruptcy court in Texas rejected J&J’s proposed bankruptcy plan to settle claims related to its talc lawsuits for the third time. In September, J&J, via a subsidiary called Red River Talc, filed ...
Pharmaceutical Technology6d
FDA awards ODD status to Sanofi’s rilzabrutinib for two rare conditions
Sanofi's reversible BTK inhibitor rilzabrutinib has gained the US Food and Drug Administration’s (FDA) orphan drug ...